An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

Study Purpose

A Study to evaluate the PK, PD, efficacy, and safety of Anifrolumab in children with moderate to severe active SLE

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 5 Years - 17 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Participant's parent/caregiver/legally authorized representative and participant (if required per local country regulation) capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
Informed assent is to be provided by the participant per local country regulation.
  • - Diagnosis of SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) criteria.
for at least 6 months prior to signing the ICF.
  • - Participant should meet all of following tuberculosis (TB) criteria: A.
No signs or symptoms of active TB B. No medical history or past physical examinations suggestive of active TB C. No recent contact with a person with active TB or if there has been such contact, referral to a TB specialist for evaluation and initiation of treatment for latent TB, if warranted, prior to the first administration of study intervention in accordance with local SoC D. No history of latent TB without documented completion of treatment prior to initial screening visit.
  • - Female participants of childbearing potential must have a negative pregnancy test at Screening.
  • - Female participants of childbearing and non-childbearing potential and male participants must adhere to the contraception methods.
  • - At screening, negative SARS-CoV-2 RT-PCR or rapid antigen test result and no known or suspected COVID-19 infection or exposure between screening and randomization visits.

Exclusion Criteria:

  • - Known diagnosis of an IFN-mediated autoinflammatory interferonopathy.
  • - History of, or current diagnosis of, clinically significant non-SLE-related vasculitides.
  • - In participants aged 11 years and above: history or evidence of suicidal ideation.
  • - History of any non-SLE disease that has required treatment with oral or parenteral corticosteroids for more than a total of 2 weeks within the last 24 weeks prior to signing the ICF.
  • - Any positive result on Screening for human immunodeficiency virus.
  • - Active hepatitis B surface antigen OR hepatitis B core antibody (HBcAb), hepatitis C virus (HCV) antibody and detectable HCV ribonucleic acid (RNA) or any severe case of Herpes Zoster infection.
  • - Any clinical cytomegalovirus or Epstein-Barr virus infection that has not completely resolved within 12 weeks prior to signing the ICF.
  • - History of severe COVID-19 infection requiring hospitalization, intensive care unit care, or assisted ventilation or any prior COVID-19 infection with unresolved sequelae.
Any mild/asymptomatic COVID-19 infection (laboratory confirmed or suspected based on clinical symptoms).
  • - Prior use of Anifrolumab.
  • - Prior treatment with directly acting cytotoxic B-cell depleting therapeutics (eg, rituximab) < 26 weeks prior to ICF signature.
  • - Blood transfusion or receipt of blood products except albumin within 4 weeks prior to signing the ICF.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05835310
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 3
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

AstraZeneca
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries Argentina, Brazil, Canada, China, Colombia, France, Germany, Italy, Japan, Mexico, Poland, Portugal, South Africa, Spain, Turkey (Türkiye), United Kingdom, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Systemic Lupus Erythematosus
Additional Details

This study aims to characterize the pharmacokinetics, pharmacodynamics, efficacy, and safety of Anifrolumab solution for infusion compared with placebo solution for infusion in pediatric participants with severe active systemic lupus erythematosus who are on background standard of care therapy. The study duration for a participant will be approximately 116 weeks, which includes:

  • - Screening period of up to 30 days.
  • - Part A consists of a four-week, single-blind, placebo-controlled, randomised, pharmacokinetic period.
  • - Part B is a double-blind, placebo-controlled, randomised, safety/efficacy period lasting 48 weeks (for rollover participants from Part A) or 52 weeks (for de novo participants).
  • - Part C is a 52-week open-label extension period.
  • - Part D is a safety follow-up period.
One safety visit at 12 weeks post last dose.

Arms & Interventions

Arms

Experimental: Anifrolumab

Randomized participants will receive a single dose of Anifrolumab via IV infusion every 4 weeks

Placebo Comparator: Placebo

Randomized participants will receive matching placebo via IV infusion

Interventions

Biological: - Anifrolumab

Participants will receive a single dose of Anifrolumab via IV infusion.

Drug: - Placebo

Participants will receive matching placebo via IV infusion

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Research Site, Phoenix 5308655, Arizona 5551752

Status

Recruiting

Address

Research Site

Phoenix 5308655, Arizona 5551752, 85016

Research Site, Los Angeles 5368361, California 5332921

Status

Recruiting

Address

Research Site

Los Angeles 5368361, California 5332921, 90027

Research Site, Washington D.C. 4140963, District of Columbia 4138106

Status

Not yet recruiting

Address

Research Site

Washington D.C. 4140963, District of Columbia 4138106, 20010

Research Site, Chicago 4887398, Illinois 4896861

Status

Recruiting

Address

Research Site

Chicago 4887398, Illinois 4896861, 60611

Research Site, Chicago 4887398, Illinois 4896861

Status

Recruiting

Address

Research Site

Chicago 4887398, Illinois 4896861, 60637

Research Site, Bethesda 4348599, Maryland 4361885

Status

Withdrawn

Address

Research Site

Bethesda 4348599, Maryland 4361885, 20889

Research Site, Saint Paul 5045360, Minnesota 5037779

Status

Recruiting

Address

Research Site

Saint Paul 5045360, Minnesota 5037779, 55125

Research Site, New Hyde Park 5128514, New York 5128638

Status

Recruiting

Address

Research Site

New Hyde Park 5128514, New York 5128638, 11042

Research Site, New York 5128581, New York 5128638

Status

Recruiting

Address

Research Site

New York 5128581, New York 5128638, 10032

Research Site, The Bronx 5110266, New York 5128638

Status

Recruiting

Address

Research Site

The Bronx 5110266, New York 5128638, 10467

Research Site, Valhalla 5142090, New York 5128638

Status

Recruiting

Address

Research Site

Valhalla 5142090, New York 5128638, 10595

Research Site, Durham 4464368, North Carolina 4482348

Status

Not yet recruiting

Address

Research Site

Durham 4464368, North Carolina 4482348, 27710

Research Site, Cincinnati 4508722, Ohio 5165418

Status

Recruiting

Address

Research Site

Cincinnati 4508722, Ohio 5165418, 45229

Research Site, Cleveland 5150529, Ohio 5165418

Status

Recruiting

Address

Research Site

Cleveland 5150529, Ohio 5165418, 44109

Research Site, Columbus 4509177, Ohio 5165418

Status

Recruiting

Address

Research Site

Columbus 4509177, Ohio 5165418, 43203

Research Site, Portland 5746545, Oregon 5744337

Status

Recruiting

Address

Research Site

Portland 5746545, Oregon 5744337, 97227

Research Site, Philadelphia 4560349, Pennsylvania 6254927

Status

Recruiting

Address

Research Site

Philadelphia 4560349, Pennsylvania 6254927, 19104

Research Site, Greenville 4580543, South Carolina 4597040

Status

Withdrawn

Address

Research Site

Greenville 4580543, South Carolina 4597040, 29605

Research Site, El Paso 5520993, Texas 4736286

Status

Recruiting

Address

Research Site

El Paso 5520993, Texas 4736286, 79902

Research Site, Houston 4699066, Texas 4736286

Status

Recruiting

Address

Research Site

Houston 4699066, Texas 4736286, 77030

Research Site, Salt Lake City 5780993, Utah 5549030

Status

Recruiting

Address

Research Site

Salt Lake City 5780993, Utah 5549030, 84108

International Sites

Research Site, Buenos Aires 3435910, Argentina

Status

Withdrawn

Address

Research Site

Buenos Aires 3435910, , C1270

Research Site, Córdoba 3860259, Argentina

Status

Not yet recruiting

Address

Research Site

Córdoba 3860259, , 5000

Research Site, Rosario 3838583, Argentina

Status

Not yet recruiting

Address

Research Site

Rosario 3838583, , S2000PBJ

Research Site, Botucatu 3469136, Brazil

Status

Recruiting

Address

Research Site

Botucatu 3469136, , 18610-070

Research Site, Curitiba 3464975, Brazil

Status

Recruiting

Address

Research Site

Curitiba 3464975, , 80030-110

Research Site, Porto Alegre 3452925, Brazil

Status

Recruiting

Address

Research Site

Porto Alegre 3452925, , 90035-903

Research Site, Ribeirão Preto 3451328, Brazil

Status

Recruiting

Address

Research Site

Ribeirão Preto 3451328, , 14048-900

Research Site, São Paulo 3448439, Brazil

Status

Recruiting

Address

Research Site

São Paulo 3448439, , 04024-002

Research Site, São Paulo 3448439, Brazil

Status

Recruiting

Address

Research Site

São Paulo 3448439, , 05403 000

Research Site, Vancouver 6173331, British Columbia 5909050, Canada

Status

Recruiting

Address

Research Site

Vancouver 6173331, British Columbia 5909050, V6H 3N1

Research Site, Toronto 6167865, Ontario 6093943, Canada

Status

Recruiting

Address

Research Site

Toronto 6167865, Ontario 6093943, M5G 1X8

Research Site, Beijing 1816670, China

Status

Not yet recruiting

Address

Research Site

Beijing 1816670, , 100020

Research Site, Beijing 1816670, China

Status

Recruiting

Address

Research Site

Beijing 1816670, , 100730

Research Site, Changchun 2038180, China

Status

Recruiting

Address

Research Site

Changchun 2038180, , 130021

Research Site, Changsha 1815577, China

Status

Recruiting

Address

Research Site

Changsha 1815577, , 410007

Research Site, Shanghai 1796236, China

Status

Recruiting

Address

Research Site

Shanghai 1796236, , 201102

Research Site, Suzhou 1886760, China

Status

Recruiting

Address

Research Site

Suzhou 1886760, , 215002

Research Site, Wenzhou 1791388, China

Status

Recruiting

Address

Research Site

Wenzhou 1791388, , 325027

Research Site, Zhengzhou 1784658, China

Status

Recruiting

Address

Research Site

Zhengzhou 1784658, , 450018

Research Site, Barranquilla 3689147, Colombia

Status

Not yet recruiting

Address

Research Site

Barranquilla 3689147, , 01800

Research Site, Medellín 3674962, Colombia

Status

Withdrawn

Address

Research Site

Medellín 3674962, , 050034

Research Site, Bordeaux 3031582, France

Status

Recruiting

Address

Research Site

Bordeaux 3031582, , 33076

Research Site, Bron 3029931, France

Status

Recruiting

Address

Research Site

Bron 3029931, , 69677

Research Site, Le Kremlin-Bicêtre 3003737, France

Status

Recruiting

Address

Research Site

Le Kremlin-Bicêtre 3003737, , 94275

Research Site, Lille 2998324, France

Status

Recruiting

Address

Research Site

Lille 2998324, , 59037

Research Site, Toulouse 2972315, France

Status

Recruiting

Address

Research Site

Toulouse 2972315, , 31300

Research Site, Berlin 2950159, Germany

Status

Recruiting

Address

Research Site

Berlin 2950159, , D-13353

Research Site, Freiburg im Breisgau 2925177, Germany

Status

Recruiting

Address

Research Site

Freiburg im Breisgau 2925177, , 79106

Research Site, Sankt Augustin 2841648, Germany

Status

Recruiting

Address

Research Site

Sankt Augustin 2841648, , 53757

Research Site, Genova 8969657, Italy

Status

Recruiting

Address

Research Site

Genova 8969657, , 16148

Research Site, Milan 6951411, Italy

Status

Recruiting

Address

Research Site

Milan 6951411, , 20122

Research Site, Padua 3171728, Italy

Status

Recruiting

Address

Research Site

Padua 3171728, , 35128

Research Site, Roma 8957247, Italy

Status

Recruiting

Address

Research Site

Roma 8957247, , 00165

Research Site, Bunkyō City 11790632, Japan

Status

Recruiting

Address

Research Site

Bunkyō City 11790632, , 113-8519

Research Site, Bunkyō City 11790632, Japan

Status

Recruiting

Address

Research Site

Bunkyō City 11790632, , 113-8603

Research Site, Chiba 2113015, Japan

Status

Recruiting

Address

Research Site

Chiba 2113015, , 266-0007

Research Site, Fuchu-shi, Japan

Status

Recruiting

Address

Research Site

Fuchu-shi, , 183-8561

Research Site, Kawasaki-shi, Japan

Status

Recruiting

Address

Research Site

Kawasaki-shi, , 216-8511

Research Site, Kobe 1859171, Japan

Status

Recruiting

Address

Research Site

Kobe 1859171, , 650-0047

Research Site, Obu-shi, Japan

Status

Recruiting

Address

Research Site

Obu-shi, , 474-8710

Research Site, Shinjuku-ku, Japan

Status

Recruiting

Address

Research Site

Shinjuku-ku, , 162-8666

Research Site, Yokohama 1848354, Japan

Status

Recruiting

Address

Research Site

Yokohama 1848354, , 232 8555

Research Site, Yokohama 1848354, Japan

Status

Recruiting

Address

Research Site

Yokohama 1848354, , 236-0004

Research Site, Guadalajara 4005539, Mexico

Status

Not yet recruiting

Address

Research Site

Guadalajara 4005539, , 44620

Research Site, Mexico 11095662, Mexico

Status

Not yet recruiting

Address

Research Site

Mexico 11095662, , 06720

Research Site, Mérida 3523349, Mexico

Status

Recruiting

Address

Research Site

Mérida 3523349, , 97070

Research Site, Monterrey 3995465, Mexico

Status

Not yet recruiting

Address

Research Site

Monterrey 3995465, , 64460

Research Site, Toluca 3515302, Mexico

Status

Not yet recruiting

Address

Research Site

Toluca 3515302, , 50170

Research Site, Lodź, Poland

Status

Recruiting

Address

Research Site

Lodź, , 91-738

Research Site, Warsaw 756135, Poland

Status

Recruiting

Address

Research Site

Warsaw 756135, , 02-637

Research Site, Wroclaw 3081368, Poland

Status

Recruiting

Address

Research Site

Wroclaw 3081368, , 52-114

Research Site, Lisbon 2267057, Portugal

Status

Suspended

Address

Research Site

Lisbon 2267057, , 1169-045

Research Site, Lisbon 2267057, Portugal

Status

Suspended

Address

Research Site

Lisbon 2267057, , 1649-035

Research Site, Porto 2735943, Portugal

Status

Suspended

Address

Research Site

Porto 2735943, , 4200-319

Research Site, Cape Town 3369157, South Africa

Status

Withdrawn

Address

Research Site

Cape Town 3369157, , 7700

Research Site, Esplugues de Llobregat 3122826, Spain

Status

Recruiting

Address

Research Site

Esplugues de Llobregat 3122826, , 8950

Research Site, Madrid 3117735, Spain

Status

Recruiting

Address

Research Site

Madrid 3117735, , 28009

Research Site, Madrid 3117735, Spain

Status

Recruiting

Address

Research Site

Madrid 3117735, , 28034

Research Site, Málaga 2514256, Spain

Status

Recruiting

Address

Research Site

Málaga 2514256, , 29011

Research Site, Valencia 2509954, Spain

Status

Recruiting

Address

Research Site

Valencia 2509954, , 46026

Research Site, Ankara 323786, Turkey (Türkiye)

Status

Recruiting

Address

Research Site

Ankara 323786, , 06230

Research Site, Istanbul 745044, Turkey (Türkiye)

Status

Recruiting

Address

Research Site

Istanbul 745044, , 34098

Research Site, Kayseri 308464, Turkey (Türkiye)

Status

Recruiting

Address

Research Site

Kayseri 308464, , 38039

Research Site, Umraniye 738377, Turkey (Türkiye)

Status

Recruiting

Address

Research Site

Umraniye 738377, , 34760

Research Site, Birmingham 2655603, United Kingdom

Status

Not yet recruiting

Address

Research Site

Birmingham 2655603, , B4 6NH

Research Site, Bristol 2654675, United Kingdom

Status

Not yet recruiting

Address

Research Site

Bristol 2654675, , BS2 8BJ

Research Site, Liverpool 2644210, United Kingdom

Status

Recruiting

Address

Research Site

Liverpool 2644210, , L12 2AP

Research Site, London 2643743, United Kingdom

Status

Recruiting

Address

Research Site

London 2643743, , NW1 2PG

Research Site, London 2643743, United Kingdom

Status

Recruiting

Address

Research Site

London 2643743, , WC1N 3JH

Research Site, Manchester 2643123, United Kingdom

Status

Not yet recruiting

Address

Research Site

Manchester 2643123, , M13 9WL

Research Site, Southampton 2637487, United Kingdom

Status

Recruiting

Address

Research Site

Southampton 2637487, , SO16 6YD